Athena Athena

X
[{"orgOrder":0,"company":"Captor Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Captor Therapeutics Presents Compelling In Vivo Proof-of-Concept Data from CT-01 Program in Hepatocellular Carcinoma","therapeuticArea":"Oncology","highestDevelopmentStatus":"Preclinical","country":"POLAND","productType":"Small molecule","productStatus":"New Molecular Entity","date":"January 2022","url1":"","url2":"","graph1":"Oncology","graph2":"Preclinical"},{"orgOrder":0,"company":"Captor Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Captor Therapeutics Announces Molecular Targets of CT-01 Program Developing TPD Therapy for Hepatocellular Carcinoma","therapeuticArea":"Oncology","highestDevelopmentStatus":"Preclinical","country":"POLAND","productType":"Small molecule","productStatus":"New Molecular Entity","date":"April 2022","url1":"","url2":"","graph1":"Oncology","graph2":"Preclinical"},{"orgOrder":0,"company":"Captor Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Captor Therapeutics Nominates the Molecular Glue CPT-6281 as Drug Candidate to Enter CTA\/IND-Enabling Studies for the Treatment of Hepatocellular Carcinoma","therapeuticArea":"Oncology","highestDevelopmentStatus":"Preclinical","country":"POLAND","productType":"Small molecule","productStatus":"New Molecular Entity","date":"August 2022","url1":"","url2":"","graph1":"Oncology","graph2":"Preclinical"},{"orgOrder":0,"company":"Captor Therapeutics","sponsor":"Ono Pharmaceutical","pharmaFlowCategory":"D","amount":"$204.1 million","upfrontCash":"Undisclosed","newsHeadline":"Ono Pharmaceutical and Captor Therapeutics Announce Drug Discovery Collaboration to Develop Small Molecule Protein Degraders for the Treatment of Neurodegenerative Diseases","therapeuticArea":"Neurology","highestDevelopmentStatus":"Discovery Platform","country":"POLAND","productType":"Small molecule","productStatus":"Undisclosed","date":"November 2022","url1":"","url2":"","graph1":"Neurology","graph2":"Discovery Platform"}]

Find Clinical Drug Pipeline Developments & Deals by Captor Therapeutics

Menu
Loading...
Filters Filter
×
FILTER:
filter Company
    filter Sponsor
      filter Country
        filter Therapeutic Area
          filter Study Phase

            Active Filter(s):

            Companies By Therapeutic Area

            Development Status

            Details:

            TPD is an approach using carefully designed small molecule drugs that can divert the body’s natural process for degrading proteins to eliminate specifically targeted disease-causing proteins.

            Lead Product(s): Undisclosed

            Therapeutic Area: Neurology Product Name: Undisclosed

            Highest Development Status: Discovery Platform Product Type: Small molecule

            Partner/Sponsor/Collaborator: Ono Pharmaceutical

            Deal Size: $204.1 million Upfront Cash: Undisclosed

            Deal Type: Collaboration November 14, 2022

            ASK
            US
            PHARMACOMPASS
            Upload
            your Pipeline Activity

            Details:

            CPT-6281 as drug candidate for the CT-01 project, which will initially focus on the clinical development of the asset as a TPD treatment against hepatocellular carcinoma (HCC).

            Lead Product(s): CPT-6281

            Therapeutic Area: Oncology Product Name: CPT-6281

            Highest Development Status: Preclinical Product Type: Small molecule

            Partner/Sponsor/Collaborator: Not Applicable

            Deal Size: Not Applicable Upfront Cash: Not Applicable

            Deal Type: Not Applicable August 10, 2022

            ASK
            US
            PHARMACOMPASS
            Upload
            your Pipeline Activity

            Details:

            Compelling in-vitro and in-vivo preclinical data demonstrate that CT-01 candidate compounds induce degradation of Eukaryotic peptide chain release factor GTP-binding subunit, and another undisclosed neo-substrate with essential function in tumorigenesis.

            Lead Product(s): CT-01

            Therapeutic Area: Oncology Product Name: CT-01

            Highest Development Status: Preclinical Product Type: Small molecule

            Partner/Sponsor/Collaborator: Not Applicable

            Deal Size: Not Applicable Upfront Cash: Not Applicable

            Deal Type: Not Applicable April 11, 2022

            ASK
            US
            PHARMACOMPASS
            Upload
            your Pipeline Activity

            Details:

            Strong and comparable efficacy was demonstrated with CT-01 candidate, also confirming the potent antitumor activity in a liver cancer mouse xenograft model and no treatment-related toxicity was observed.

            Lead Product(s): CT-01

            Therapeutic Area: Oncology Product Name: CT-01

            Highest Development Status: Preclinical Product Type: Small molecule

            Partner/Sponsor/Collaborator: Not Applicable

            Deal Size: Not Applicable Upfront Cash: Not Applicable

            Deal Type: Not Applicable January 13, 2022

            ASK
            US
            PHARMACOMPASS
            Upload
            your Pipeline Activity
            Post Enquiry
            POST ENQUIRY